NMRA ファイナンス： Neumora Therapeutics Inc AI分析

ホーム

株式

NMRA

財務状況

NMRA 財務

Neumora Therapeutics Inc

$2.57

-2.65%

$-0.07

終値： Mar 19, 16:00:00 GMT-4

$2.58

0.56%

$0.01

アフターマーケット：Mar 19, 20:00:00 GMT-4

概要予測収入配当財務状況

主要データ

前終値

$2.64

始値

$2.61

当日レンジ

$2.51 - $2.63

52週レンジ

$0.611 - $3.65

取引高

952.1K

平均取引高

1.6M

1株当たり利益(TTM)

-1.46

配当利回り

時価総額

$425.8M

NMRAとは何ですか？

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in Watertown, Massachusetts and currently employs 95 full-time employees. The company went IPO on 2023-09-15. The firm's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The firm's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).

特徴

リソース

市場

収入

貸借対照表

現金の流れ

年次

四半期

NMRA 収入

金額は百万米ドル単位。会計年度は2月から1月まで。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
収入	0	0	0	0	0	0
収益成長率（YoY）	--	--	--	--	--	--
収益のコスト	--	--	--	--	--	--
売上総利益	--	--	--	--	--	--
販売、一般および管理	63	62	45	31	24	8
研究開発	177	200	142	91	55	17
運営費用	240	263	188	122	80	25
その他の非営業収入（費用）	0	0	0	0	0	0
税引前利益	-236	-243	-235	-130	-237	-99
所得税費	0	0	0	--	--	--
純利益	-236	-243	-235	-130	-237	-99
純利益成長率	-19%	3%	81%	-45%	139%	--
流通済み株式数（希薄化後）	161.83	159.37	158.83	151.95	151.95	151.95
株式変動（前年比）	1%	0%	5%	0%	0%	0%
EPS（希薄化）	-1.46	-1.52	-1.48	-0.86	-1.56	-0.65
EPS成長率	-20%	3%	73%	-45%	140%	--
フリーキャッシュフロー	-208	-183	-167	-128	-76	-28
1株当たりフリーキャッシュフロー	--	--	--	--	--	--
粗利益	--	--	--	--	--	--
営業利益率	0%	0%	0%	0%	0%	0%
利益率	0%	0%	0%	0%	0%	0%
フリーキャッシュフロー利益率	0%	0%	0%	0%	0%	0%
EBITDA	-240	-263	-188	-122	-80	-25
EBITDAマージン	0%	0%	0%	0%	0%	0%
D&A による EBITDA	0	0	0	0	0	0
営業利益	-240	-263	-188	-122	-80	-25
営業利益率	0%	0%	0%	0%	0%	0%
実効税率	0%	0%	0%	--	--	--

Follow-Up Questions

Neumora Therapeutics Inc의 주요 재무제표는 무엇인가요?



최신 재무제표(Form-10K)에 따르면, Neumora Therapeutics Inc의 총 자산은 $316이며, 순損失입니다.

NMRA의 주요 재무 비율은 무엇인가요?



Neumora Therapeutics Inc의 유동비율은 10.89이고, 순이익률은 0, 주당 매출은 $0입니다.

Neumora Therapeutics Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?



Neumora Therapeutics Inc の最大収益セグメントは Licensing of ReadyOp Software で、最新の利益発表における収益は 2,414,949 です。地域別に見ると、United States が Neumora Therapeutics Inc の主要市場であり、収益は 3,126,148 です。

Neumora Therapeutics Inc은 수익성이 있나요?



いいえ, 최신 재무제표에 따르면 Neumora Therapeutics Inc의 순損失은 $-243입니다.

Neumora Therapeutics Inc에 부채가 있나요?



はい, Neumora Therapeutics Inc의 부채는 29입니다.

Neumora Therapeutics Inc의 발행 주식은 몇 주인가요?



Neumora Therapeutics Inc의 총 발행 주식은 161.71주입니다.

Neumora Therapeutics Inc (NMRA) 財務

NMRA 株価推移チャート